Integer Holdings Corporation (ITGR) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Integer Holdings Corporation (ITGR) Healthcare & Pipeline Overview

Integer Holdings Corporation, a medical device outsource manufacturer, serves multi-national original equipment manufacturers in the cardiac, neuromodulation, orthopedics, and vascular markets. With a focus on both medical and non-medical segments, the company provides a range of products, including implantable devices, batteries, and surgical components, maintaining a P/E ratio of 22.4.

What Is the Investment Thesis for ITGR?

Integer Holdings Corporation presents a compelling investment case based on its established position as a medical device outsource manufacturer. The company's diverse product portfolio, serving multiple high-growth medical sectors, offers revenue stability and expansion opportunities. With a P/E ratio of 22.4 and a profit margin of 7.7%, Integer demonstrates financial health. Key growth catalysts include expanding its presence in the neuromodulation and orthopedics markets. However, potential risks include increasing competition and regulatory changes in the medical device industry. The company's beta of 0.71 suggests lower volatility compared to the overall market.

Based on FMP financials and quantitative analysis

ITGR Key Highlights

Market capitalization of $4.25B, reflecting substantial investor confidence in the company's market position and growth prospects.

• P/E ratio of 22.4, indicating a reasonable valuation relative to earnings compared to the broader healthcare sector.
• Profit margin of 7.7%, showcasing the company's ability to generate profits from its revenue streams.
• Gross margin of 23.3%, reflecting the efficiency of Integer's manufacturing and supply chain operations.
• Beta of 0.71, suggesting lower volatility compared to the overall market, making it a potentially stable investment.

Who Are ITGR's Competitors?

ITGR is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are ITGR's Key Strengths?

Diverse product portfolio serving multiple medical sectors.

• Established relationships with multi-national original equipment manufacturers.
• Specialized manufacturing capabilities in medical devices and battery technology.
• Global presence with manufacturing facilities in multiple countries.

What Are ITGR's Weaknesses?

Reliance on a limited number of key customers.

• Exposure to regulatory changes in the medical device industry.
• Potential for product liability claims.
• Dependence on third-party suppliers for raw materials and components.

What Could Drive ITGR Stock Higher?

New product launches in the neuromodulation and orthopedics markets expected in late 2026.

• Increasing demand for medical device outsourcing due to cost pressures on OEMs.
• Expansion of manufacturing facilities in emerging markets to support geographic growth.

What Are the Key Risks for ITGR?

Regulatory changes in the medical device industry could increase compliance costs.

• Economic downturns could reduce healthcare spending and demand for medical devices.
• Competition from other medical device manufacturers could erode market share.
• Product liability claims could result in significant financial losses.

What Are the Growth Opportunities for ITGR?

• Growth opportunity 1: Expansion in Neuromodulation: Integer can capitalize on the growing neuromodulation market, projected to reach $13.3 billion by 2027. By developing and manufacturing advanced neuromodulation devices, such as spinal cord stimulators and deep brain stimulators, Integer can increase its market share. This expansion requires strategic partnerships with neuromodulation device companies and investments in research and development to create innovative products.
• Growth opportunity 2: Penetration of the Orthopedics Market: The global orthopedics market is expected to reach $52.5 billion by 2028. Integer can increase its presence in this market by offering a wider range of orthopedic instruments and implants. This includes instruments used in hip, knee, and spine surgeries, as well as reamers and chisels. Strategic acquisitions of specialized orthopedic component manufacturers could accelerate this growth.
• Growth opportunity 3: Advanced Surgical Device Manufacturing: The advanced surgical device market is experiencing rapid growth, driven by demand for minimally invasive surgical techniques. Integer can expand its offerings in this area by manufacturing harmonic scalpels, shaver blades, burr shavers, and radio frequency probes. Investing in advanced manufacturing technologies, such as robotic assembly and 3D printing, will be crucial for maintaining a competitive edge.
• Growth opportunity 4: Customized Battery Solutions for Medical Devices: The market for medical device batteries is growing due to the increasing use of portable and implantable medical devices. Integer can leverage its expertise in battery technology to provide customized battery power and power management systems for medical device manufacturers. This includes rechargeable batteries, non-rechargeable batteries, and chargers. Focusing on high-performance and long-lasting battery solutions will be key.
• Growth opportunity 5: Geographic Expansion in Emerging Markets: Emerging markets, such as China and India, are experiencing rapid growth in healthcare spending. Integer can expand its presence in these markets by establishing manufacturing facilities and distribution networks. This geographic expansion will require adapting its product offerings to meet the specific needs of these markets and navigating local regulatory requirements.

What Threats Does ITGR Face?

• Increasing competition from other medical device manufacturers.
• Economic downturns affecting healthcare spending.
• Technological obsolescence.
• Fluctuations in currency exchange rates.

What Are ITGR's Competitive Advantages?

• Established relationships with multi-national original equipment manufacturers.
• Specialized manufacturing capabilities in medical devices and battery technology.
• Diverse product portfolio serving multiple high-growth medical sectors.
• Global presence with manufacturing facilities in multiple countries.

What Does ITGR Do?

Founded in 1970 and headquartered in Plano, Texas, Integer Holdings Corporation operates as a medical device outsource manufacturer, serving the United States, Puerto Rico, Costa Rica, and international markets. The company functions through two primary segments: Medical and Non-Medical. Integer provides a diverse array of products used in interventional cardiology, structural heart procedures, heart failure treatments, peripheral vascular interventions, neurovascular procedures, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, urology, and gastroenterology. Integer's offerings include cardiac rhythm management products like implantable pacemakers and defibrillators, neuromodulation products such as spinal cord stimulators, and a variety of batteries, feedthroughs, device enclosures, and machined components. The company also supplies arthroscopic, laparoscopic, and general surgery devices, along with orthopedic products and customized battery power solutions. Integer serves multi-national original equipment manufacturers and their subsidiaries in the cardiac, neuromodulation, orthopedics, vascular, advanced surgical, and portable medical markets. Integer has a market capitalization of $4.25B and employs approximately 11,000 people.

What Products and Services Does ITGR Offer?

• Manufactures medical devices for interventional cardiology.
• Provides products for structural heart procedures.
• Offers solutions for heart failure management.
• Manufactures devices for peripheral vascular interventions.
• Provides products for neuromodulation, including spinal cord stimulators.
• Offers orthopedic products, including surgical instruments.
• Manufactures customized battery power and power management systems.
• Provides medical technologies for various applications.

How Does ITGR Make Money?

• Outsource manufacturing of medical devices for original equipment manufacturers (OEMs).
• Provides products and services to both medical and non-medical segments.
• Customized battery power and power management systems for various markets.
• Serves multi-national corporations and their subsidiaries.

What Industry Does ITGR Operate In?

Integer Holdings Corporation operates within the medical device industry, a sector characterized by continuous innovation and increasing demand due to an aging global population and advancements in medical technology. The market is competitive, with companies vying for contracts with original equipment manufacturers. Trends include a growing emphasis on minimally invasive procedures and the development of smart medical devices. Integer's focus on outsourcing positions it to capitalize on the increasing need for specialized manufacturing capabilities within the medical device industry. The company competes with CON: Concentra Group Holdings Parent, Inc. and other specialized manufacturers.

Who Are ITGR's Key Customers?

• Multi-national original equipment manufacturers (OEMs) in the medical device industry.
• Affiliated subsidiaries of these OEMs.
• Companies in the cardiac, neuromodulation, orthopedics, vascular, and advanced surgical markets.
• Customers in the portable medical market.

Wall Street analysts project Integer Holdings Corporation revenue of about $1.82B for fiscal 2026, with EPS near $6.12. The estimate reflects 8 contributing analysts.

Integer Holdings Corporation's Piotroski F-Score is 7/9, a 9-point checklist of profitability, leverage and efficiency — signaling solid underlying fundamentals. Its Altman Z-Score of 2.83 places it in the grey zone, a middle ground that warrants monitoring.

Return on equity for Integer Holdings Corporation stands at 8.2%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 4.2%, showing how much profit it generates from its asset base. ITGR trades at a trailing price-to-earnings ratio of 22.39, roughly in line with the Healthcare sector average of ~23x. Its free cash flow yield is 3.1%, a gauge of the cash the business throws off relative to its market value. A current ratio of 3.75 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 4.4%, the inverse of the P/E and a quick read on earnings relative to price.

Integer Holdings Corporation (ITGR) Valuation Context

Valued at $4.25B, ITGR is classified as a mid-cap stock. Relative to its peer group, ITGR's quantitative score of 71/100 is below the peer average of 85/100.

Company Profile

Integer Holdings Corporation operates in the Medical - Devices industry within the Healthcare sector. It is headquartered in Plano, US. The company is led by CEO Payman Khales. ITGR has traded publicly since 2000.

ITGR Financials

ITGR Latest News

ITGR Analyst Consensus

ITGR MoonshotScore

Latest Integer Holdings Corporation Analysis

ITGR Healthcare Stock FAQ

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources